Cocrystal Pharma Inc (COCP)

In the past six months, Cocrystal Pharma's stock price has been impacted by several events. The company announced that its norovirus drug candidate, CDI-988, received FDA Fast Track Designation, leading to a surge in the stock price. Cocrystal Pharma reported its 2025 financial results and provided updates on its antiviral drug-development programs. The first subjects were dosed in its Phase 1b study evaluating CDI-988 for norovirus prevention and treatment. Cocrystal Pharma announced plans to extend enrollment in its Phase 2a influenza challenge study with CC-42344 due to unexpectedly low influenza infection rates among participants, though the drug candidate showed a favorable safety profile.

Demand for Cocrystal Pharma's influenza-related products, such as CC-42344, is likely to exhibit seasonality due to influenza outbreaks primarily occurring during the winter months. While norovirus can cause acute viral gastroenteritis, the provided information does not explicitly detail a specific seasonal pattern for its outbreaks, though viral infections often have seasonal trends.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. The company utilizes a proprietary structure-based drug discovery platform and Nobel Prize-winning expertise to design small-molecule antivirals, primarily focusing on developing treatments for influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. Key product candidates include CDI-988, an oral pan-viral 3CL protease inhibitor for norovirus and coronavirus infections; CC-42344, a novel oral PB2 inhibitor for influenza A; and CC-31244, a Hepatitis C virus non-nucleoside inhibitor.

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, with an additional office in Miami, Florida, and a subsidiary, Cocrystal Pharma Australia, Pty LTD, in Melbourne, Australia. Clinical studies have been conducted in locations such as Australia and the United Kingdom.

Cocrystal Pharma has a news sentiment score of 0.78, indicating a generally positive sentiment. The company has seen increased news coverage, with 12 articles tracked in a recent week compared to an average of 2. The recent FDA Fast Track designation for CDI-988 enhances the company's reputation and highlights progress in its pipeline. The company operates in the high-risk, high-reward biotechnology sector, where reputation is closely tied to clinical trial success and regulatory milestones.

The ownership structure of Cocrystal Pharma (COCP) stock includes institutional, retail, and individual investors. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, Geode Capital Management, Llc, BlackRock, Inc., T3 Companies, LLC, DRW Securities, LLC, Neuberger Berman Group LLC, State Street Corp, XTX Topco Ltd, and Two Sigma Securities, Llc. Insiders hold a significant portion of the company's stock, with approximately 45.08% owned by insiders. Steven D. Rubin owns the most shares, and Phillip Frost, a board member, has made several share purchases in the past year.